- Home
- CNR vs MIRM Comparison
CNR vs MIRM Comparison
Compare CNR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNR
- MIRM
- Stock Information
- Founded
- CNR 1864
- MIRM 2018
- Country
- CNR United States
- MIRM United States
- Employees
- CNR N/A
- MIRM N/A
- Industry
- CNR Coal Mining
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- CNR Energy
- MIRM Health Care
- Exchange
- CNR Nasdaq
- MIRM Nasdaq
- Market Cap
- CNR 4.4B
- MIRM 3.8B
- IPO Year
- CNR N/A
- MIRM 2019
- Fundamental
- Price
- CNR $80.61
- MIRM $69.03
- Analyst Decision
- CNR Strong Buy
- MIRM Strong Buy
- Analyst Count
- CNR 5
- MIRM 11
- Target Price
- CNR $110.10
- MIRM $79.00
- AVG Volume (30 Days)
- CNR 1.1M
- MIRM 600.6K
- Earning Date
- CNR 11-06-2025
- MIRM 11-04-2025
- Dividend Yield
- CNR 0.50%
- MIRM N/A
- EPS Growth
- CNR N/A
- MIRM N/A
- EPS
- CNR 0.51
- MIRM N/A
- Revenue
- CNR $3,275,589,000.00
- MIRM $429,161,000.00
- Revenue This Year
- CNR $93.87
- MIRM $53.14
- Revenue Next Year
- CNR $8.40
- MIRM $19.83
- P/E Ratio
- CNR $157.64
- MIRM N/A
- Revenue Growth
- CNR 47.13
- MIRM 62.33
- 52 Week Low
- CNR $58.19
- MIRM $36.88
- 52 Week High
- CNR $134.59
- MIRM $78.55
- Technical
- Relative Strength Index (RSI)
- CNR 40.91
- MIRM 41.22
- Support Level
- CNR $79.54
- MIRM $66.99
- Resistance Level
- CNR $93.07
- MIRM $71.96
- Average True Range (ATR)
- CNR 4.29
- MIRM 2.37
- MACD
- CNR -2.04
- MIRM -0.55
- Stochastic Oscillator
- CNR 4.55
- MIRM 20.38
About CNR Core Natural Resources Inc. Common Stock
Core Natural Resources Inc is a producer and exporter of coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The principal activity involves mining, preparation, and marketing of thermal coal, sold to power generators.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.